A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin

Author： Yiu Kai-Hang   Cheung Bernard MY   Tse Hung-Fat  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.19, Iss.3, 2010-03, pp. : 437-449

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Safety and Efficacy of a Combination of Niacin Extended Release and Simvastatin in Patients with Dyslipidemia: The OCEANS Study

By Karas Richard H.  

American Journal of Cardiovascular Drugs, Vol. 8, Iss. 2, 2008-01 ,pp. : 69-81

Adis International

Access to resources Recommend Favorite

Benefits of niacin/laropiprant combo come under question

By  

Reactions Weekly, Vol. 1, Iss. 1434, 2013-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Niacin/laropiprant offers a lipid-altering experience

By  

Inpharma, Vol. 1, Iss. 1604, 2007-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Niacin/laropiprant [MK0524A] not approvable in US.

By  

Inpharma, Vol. 1, Iss. 1637, 2008-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

Extended-Release Niacin (Nicotinic Acid)/Laropiprant

By Perry Caroline M.  

Drugs, Vol. 69, Iss. 12, 2009-08 ,pp. : 1665-1679

Adis International

Access to resources Recommend Favorite